Dry-powder Tyvaso Found More Convenient Than Nebulizer for PAH Patients

Dry-powder Tyvaso Found More Convenient Than Nebulizer for PAH Patients

284760

Dry-powder Tyvaso Found More Convenient Than Nebulizer for PAH Patients

Switching from the approved Tyvaso (inhaled treprostinil) nebulizer to Tyvaso DPI — an investigational dry-powder formulation — is safe, effective, and likely more convenient for people with pulmonary arterial hypertension (PAH), top-line data from the Phase 1 BREEZE trial show. These positive findings also were supported by data from a study involving healthy volunteers. That data showed that United Therapeutics‘ new breath-powered inhaler led to treatment exposures comparable to those achieved with its existing Tyvaso…

You must be logged in to read/download the full post.